复发性事件与终末事件数据的应答自适应治疗分配
针对长期临床研究中复发性事件过程可被死亡等终末事件终止的特点,该文基于联合脆弱模型计算限制性随机化所需样本量,并提出以最优分配为目标的应答自适应随机化程序(双重自适应有偏硬币设计)。所提方案能在达到最优目标的同时减少接受劣效治疗的受试者人数,并保持与限制性随机化设计相当的检验效能;以COAPT试验和A-HeFT试验进行示例说明。
要点
- 基于联合脆弱模型可对复发性事件与终末事件过程进行联合分析。
- 双重自适应有偏硬币设计以最优分配为目标实施应答自适应随机化。
- 该方案可减少接受劣效治疗的受试者人数且检验效能与限制性随机化相当。
核心结论
- 所提出的应答自适应治疗分配方案可减少接受劣效治疗的试验参与者人数,同时达到最优目标,并保持与限制性随机化设计相当的检验效能。
研究设计与样本
- 针对双臂临床试验设计,基于限制性随机化计算所需样本量,并提出基于联合脆弱模型的复发性事件与终末事件结局的应答自适应随机化程序。
- 实施以最优分配为目标的双重自适应有偏硬币设计随机化程序。
主要发现
- 所提出的自适应治疗分配方案被证明能够减少接受劣效治疗的试验参与者人数,同时达到最优目标。
- 与限制性随机化设计相比,所提方案保持相当的检验效能。
- 采用COAPT试验和A-HeFT试验两项临床研究说明所提程序的优势。
临床怎么用
- 在长期随访且存在死亡等终末事件的临床试验中,可考虑采用基于联合脆弱模型的应答自适应随机化以增加受试者分配至有效治疗的比例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In long-term clinical studies, recurrent event data are frequently collected to contrast the efficacy of two different treatments. However, the recurrent event process can be stopped by a terminal event, such as death. For analyzing recurrent event and terminal event data, joint frailty modeling has recently received considerable attention because it makes it possible to study the joint evolution over time of both recurrent and terminal event processes and gives consistent and efficient parameters. For a two-arm clinical trial design based on these data sets, there has been limited research on investigating the balanced design, let alone adaptive treatment allocation. Although equal sample size allocation obtained for both treatments is intuitively first adopted in a trial design, if one treatment is expected to be superior, it may be desirable to allocate more subjects to the effective treatment. In this article, we calculate the required sample size based on restricted randomization and then propose a target response-adaptive randomization procedure for recurrent and terminal event outcomes based on the joint frailty model. A randomization procedure, the doubly adaptive biased coin design that targets some optimal allocations, is implemented. The proposed adaptive treatment allocation schemes have been shown to be capable of reducing the number of trial participants who receive inferior treatment while simultaneously reaching an optimal target, as well as retaining a comparable test power as compared to a restricted randomization design. Finally, two clinical studies, the COAPT trial and the A-HeFT trial, are used to illustrate the advantages of adopting the proposed procedure.
引用
- Su PF. Response-adaptive treatment allocation for clinical studies with recurrent event and terminal event data. Stat Med. 2021. PMID: 34693543. doi:10.1002/sim.9235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。